WASHINGTON (AP) — Novavax's closely watched COVID-19 vaccine is on track for full approval after additional discussions with the Food and Drug Administration, the company said Wednesday. The ...

Novavax stock was up on Monday amid roiling uncertainty about its Covid-19 vaccine approval, which has been caught up in the turbid health politics of the second Trump administration.

FDA scrutiny of Novavax COVID-19 vaccine sparks uncertainty about other shots A vial of the Phase 3 Novavax coronavirus vaccine prepared for use in a trial at St. George's University hospital in ...

Earlier this summer the FDA asked Moderna for more efficacy data on its flu vaccine before it could review an mRNA-based ...

The Novavax Covid-19 vaccine, which uses more traditional protein-based technology than the mRNA vaccines from Pfizer/BioNTech and Moderna, has been subject to emergency use authorization since 2022.

Novavax makes the nation’s only traditional protein-based coronavirus vaccine – and until now it had emergency authorization from FDA for use in anyone 12 and older.

The Trump administration's effort to impose new requirements on Novavax's COVID-19 vaccine is sowing uncertainty about other vaccines, too.

WASHINGTON — Novavax's closely watched COVID-19 vaccine is on track for full approval after additional discussions with the Food and Drug Administration, the company said Wednesday.

Novavax originally showed its vaccine was safe and effective in a 30,000-person clinical trial. The FDA had been on track to grant Novavax full approval – without restrictions -- by its April 1 ...

A vial of the Phase 3 Novavax coronavirus vaccine prepared for use in a trial at St. George’s University hospital in London, Oct. 7, 2020. (AP Photo/Alastair Grant, File) ...

WASHINGTON (AP) — Novavax's closely watched COVID-19 vaccine is on track for full approval after additional discussions with the Food and Drug Administration, the company said Wednesday.